Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
Shattuck Labs, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05483933CT.gov Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Peritoneal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mirvetuximab (this asset) | Shattuck Labs, Inc. | P1 | CC · 46 |
| Cis-Diamminedichloroplatinum Ii | GOG Foundation | P3 | BBB |
| Carboplatin | University of Washington | P3 | BBB |
| Nogitecan | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BBB |
| Adriamycin | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BBB |
| Pegfilgrastim | TORL Biotherapeutics, LLC | P2/3 | BBB |
| Nivestim | Roswell Park Cancer Institute | P2 | BBB |
| Mirvetuximab Soravtansine | AbbVie | P3 | BB |
| Durvalumab | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Primary Peritoneal Carcinoma cohort
Other indications for Mirvetuximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fallopian Tube Carcinoma | — | P1 | CC · 46 |
| Ovarian Cancer | — | P1 | CC · 44 |
| Ovarian Carcinoma | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mirvetuximab in Primary Peritoneal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mirvetuximab-primary-peritoneal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →